• BYSI sold all ownership interests in BeyondSpring Ltd. to Biolin Investment under a share purchase and collaboration agreement.
• Deal closed Sept. 30, 2026.
• Consideration was noncash, led by a perpetual, royalty-free license to DUBLIN-4 trial data generated in mainland China.
• Investor committed to fund Bulin’s conduct of the trial and delivery of datasets, case report forms, and source data.
• Clawback allows equity return if enrollment targets are missed within three years, including full return if the shortfall is 90% or more.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006465), on October 06, 2026, and is solely responsible for the information contained therein.